The Governing Council of the University of Toronto

Innogen Pharmaceutical, founded by a leading Chinese diabetes researcher, applied for a Hong Kong IPO. Its first commercial product, a humanized long-acting GLP-1 receptor agonist, is expected to launch in H1 2025. Despite heavy losses, the company has raised over 1.51 billion yuan and faces stiff competition in the crowded diabetes and obesity drug market.

Bausch + Lomb acquires Elios Vision, Inc., enhancing its glaucoma treatment portfolio with the ELIOS™ MIGS procedure, a clinically validated, implant-free surgery. The acquisition aims to address the rising glaucoma prevalence, leveraging Bausch + Lomb's global reach for widespread adoption. Despite strong financial performance, analysts express caution over stock valuation.

The Phase III AALL1731 trial showed Blincyto (blinatumomab) significantly improved three-year disease-free survival (DFS) in pediatric patients with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) when added to chemotherapy, with a 61% decrease in relapse risk. The trial's interim analysis led to early termination due to the observed benefit, highlighting Blincyto's potential as a transformative treatment in this patient population.

Ovary removal before age 50, combined with APOE4 gene, significantly raises Alzheimer's risk; hormone replacement therapy (HRT) can mitigate this risk.

Santiago, diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), participated in a clinical trial combining chemotherapy with blinatumomab, showing a 61% reduction in relapse risk. The study, published in the New England Journal of Medicine, indicates blinatumomab significantly improves disease-free survival, potentially becoming the new standard of care for B-ALL patients.

A clinical trial combining standard chemotherapy with blinatumomab for newly diagnosed B-ALL in children showed a 61% reduction in relapse or death risk, significantly improving disease-free survival rates, marking a new standard of care in childhood cancer treatment.

Regeneron Pharmaceuticals reported positive phase 3 trial results for pozelimab plus cemdisiran in treating paroxysmal nocturnal haemoglobinuria (PNH), showing superior efficacy over standard treatments. The combination achieved higher rates of LDH control and normalization, indicating significant progress in PNH treatment and potential for broader application in complement-mediated diseases.

Phase 3 trial data showed the poze-cemdi combination treatment achieved better disease control in PNH patients, measured by LDH levels, compared to ravulizumab. Poze-cemdi, combining an antibody and siRNA targeting C5, demonstrated superior LDH control and normalization, with potential for self-administration, indicating a promising treatment approach for PNH and other complement-mediated diseases.

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk B-cell acute lymphoblastic leukemia (B-ALL), with a 3-year DFS of 96%.

Adding BLINCYTO to chemotherapy significantly improves disease-free survival in pediatric patients with B-cell acute lymphoblastic leukemia, with a 3-year DFS of 96% compared to 87.9% with chemotherapy alone.